文献速递淋巴瘤

Castleman病概述

Overview of Castleman disease.
PubMed 文献 · Blood · 2020-01-01

Castleman病(CD)是一组至少包含4种疾病的统称,共享特征性组织病理学表现但病因、表现、治疗和结局差异广泛。CD包括单中心型CD(UCD)和多中心型CD(MCD),后者分为特发性MCD(iMCD)、HHV8相关MCD和POEMS相关MCD。iMCD可进一步分为iMCD-TAFRO和iMCD-NOS。自1954年首次描述以来,诊断、分类、发病机制和治疗取得实质性进展,抗逆转录病毒治疗和利妥昔单抗改善了HHV8-MCD结局,抗IL-6靶向治疗对许多iMCD患者高效。

要点

  • CD分为UCD和MCD,MCD包括iMCD、HHV8-MCD和POEMS-MCD,iMCD再分TAFRO和NOS。
  • HHV8-MCD受益于抗逆转录病毒治疗和利妥昔单抗,结局改善。
  • 抗IL-6靶向治疗对许多iMCD患者高度有效,难治病例需其他治疗。

核心结论

  • CD是一组至少4种共享组织病理学特征但病因、表现、治疗和结局广泛的疾病。
  • HHV8-MCD经抗逆转录病毒治疗和利妥昔单抗治疗结局改善。
  • 抗IL-6靶向治疗对许多iMCD患者高度有效,但难治病例仍需其他治疗。

研究设计与样本

  • 综述,总结Castleman病的诊断、分类、发病机制和治疗进展。

主要发现

  • CD包括UCD和MCD,MCD分为iMCD、HHV8-MCD和POEMS-MCD。
  • iMCD可进一步分为iMCD-TAFRO和iMCD-NOS。
  • 自1954年UCD首次描述以来,诊断、分类、发病机制和治疗取得实质性进展。

关键数值与推荐

  • iMCD亚型包括iMCD-TAFRO(血小板减少、腹水、网状纤维化、肾功能不全、器官肿大)和iMCD-NOS。

临床怎么用

  • HHV8-MCD可采用抗逆转录病毒治疗和利妥昔单抗。
  • iMCD可使用抗IL-6靶向治疗,难治病例需其他治疗。
  • 可鼓励患者自我入组CDCN的ACCELERATE自然病史注册研究(#NCT02817997)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Castleman disease (CD) describes a group of at least 4 disorders that share a spectrum of characteristic histopathological features but have a wide range of etiologies, presentations, treatments, and outcomes. CD includes unicentric CD (UCD) and multicentric CD (MCD), the latter of which is divided into idiopathic MCD (iMCD), human herpes virus-8 (HHV8)-associated MCD (HHV8-MCD), and polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes (POEMS)-associated MCD (POEMS-MCD). iMCD can be further subclassified into iMCD-thrombocytopenia, ascites, reticulin fibrosis, renal dysfunction, organomegaly (iMCD-TAFRO) or iMCD-not otherwise specified (iMCD-NOS). Advances in diagnosis, classification, pathogenesis, and therapy are substantial since the original description of UCD by Benjamin Castleman in 1954. The advent of effective retroviral therapy and use of rituximab in HHV8-MCD have improved outcomes in HHV8-MCD. Anti-interleukin-6-directed therapies are highly effective in many iMCD patients, but additional therapies are required for refractory cases. Much of the recent progress has been coordinated by the Castleman Disease Collaborative Network (CDCN), and further progress will be made by continued engagement of physicians, scientists, and patients. Progress can also be facilitated by encouraging patients to self-enroll in the CDCN's ACCELERATE natural history registry (#NCT02817997; www.CDCN.org/ACCELERATE).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020. PMID: 32106302. doi:10.1182/blood.2019000931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。